Manufacturing Facilities
Delivering high quality products across the globe

Monroe, US

Spread across 105,000 sq.ft., this facility will manufacture sterile and oral solids, injectable and nebulized products.
Estimated investment is approximately USD 100 Mn over 5 years.

Regulatory Approvals

  • US-FDA

Markets

USA

Annual Capacity

Oral solids: 300 - 400 Mn tablets and capsules

Injectables: 20 - 25 Mn vials and pre-filled syringes

Inhalation: 25 - 30 mn ampules

Goa, India

The facility commenced operations in 2004.
Three manufacturing facilities for production of:
  • Oral – solids
  • Semi-solids
  • Hormones (oral solids)

ISO 14001: 2015, ISO 45001: 2018

Regulatory Approvals

  • US-FDA
  • MCC South Africa
  • WHO – GMP
  • ANVISA Brazil
  • MHRA UK
  • RU – GMP Russia
  • SUKL - CZ

Markets

North America, Western Europe

Annual Capacity

Oral solid dosages (OSD): 400 Mn tablets and 100 Mn capsules

Semi-solids: 2.75 Mn tubes

Hormone: 40 Mn tablets

Baddi, India

This state-of-the-art manufacturing facility commenced operations in 2005.
The facility caters to the production of oral solids and liquid orals, external preparations like lotions, creams and respiratory segment products.

ISO 14001: 2015 approved, ISO 45001: 2018

Regulatory Approvals

  • WHO GMP
  • US FDA
  • ANVISA BRAZIL
  • UK-MHRA (EU)
  • SUKL- CZECH REPUBLIC
  • UKRAINIAN-GMP
  • MCC
  • MOH RUSSIA
  • ZAZIBONA
  • NAMIBIA MEDICINES REGULATORY COUNCIL NAMIBIA
  • ZIMBABWE
  • TFDA TANZANIA
  • ZANZIBAR
  • GULF CO-OPERATION COUNCIL (GCC)
  • RU-GMP
  • MEXICO (COFEPRIS)

Markets

USA, Europe, India, Brazil, Ukraine, Russia, Argentina & Mexico, Other semi-regulated markets for specific dosage forms

Annual Capacity

Oral solids: 900 Mn tablets / capsules

Liquids: 40 Mn bottles

Semisolids: 20 Mn Tubes/Bottles

Respiratory segment: 15 Mn Units

Nalagarh, India

The facility commenced operations in 2009.
The plant has three main sections for manufacturing liquid, ointments/creams and lotions.

ISO 14001: 2004 approved, ISO 22716 : GMP for Cosmetics

Regulatory Approvals

  • FDA Philippines
  • TFDA - Tanzania
  • NDA – Uganda
  • FDA- Kenya
  • WHO-GMP
  • Local FDA

Markets

India, Asia, Africa

Annual Capacity

Oral liquids: 64 million bottles

Ointments and creams: 64 million units

Lotions: 32 million bottles

Sikkim, India

Established in 2012, the facility is focused on manufacturing oral solid dosages.

ISO 14001: 2015 Approved, ISO 45001: 2018 Approved

Regulatory Approvals

  • Local FDA

Markets

India

Annual Capacity

Oral Solid dosages : 1650 million tablets

Nashik, India

Glenmark’s first manufacturing unit, it began operations in 1983.
The facility manufactures products catering to demand in oral solids, liquid orals, external creams and powder shampoo.

ISO 14001: 2015, OHSAS 45001: 2018

Regulatory Approvals

  • WHO – GMP
  • ANVISA (Brazil)
  • NDA – Uganda
  • MOH – Nigeria
  • TFDA – Tanzania
  • MOH – Ethiopia
  • MOH – Congo
  • UKRAINIAN -GMP
  • MCC – South Africa
  • MOH – Oman
  • MOH – Ukraine
  • INVIMA – Columbia
  • SAUMP-Ukraine
  • RU – GMP Russia

Markets

Asia, India, Africa, CIS / Russia, Latin America

Annual Capacity

Oral solids: 222 Mn tablets / capsules per year

Oral Liquids: 15.6 Mn bottles per year

External preparations: 48 Mn units per year

Powder Shampoo: 2.4 Mn units per year

Indore, India

The Indore facility initiated operations in May 2009.

ISO 14001: 2004 approved

Click to view the Biomedical waste generation data 2020-21

Regulatory Approvals

  • US-FDA
  • UK MHRA
  • WHO – GMP

Markets

North America, Europe

Annual Capacity

Oral solid dosages: 1490 Mn tablets

Immuno Suppressant Block:Capsules – 42 Mn

Ointment & Creams – 80 MT

Buenos Aires, Argentina

The Glenmark manufacturing site at Buenos Aires, Argentina is focused on manufacturing of Oncology Injectables.
The plant is spread across 30,000 sq. ft. and it serves as a global hub for manufacturing Lyophilized and Liquid Injectables used in oncology therapies.

ISO 14001: 2015 approved , ISO 45001: 2018 approved

Regulatory Approvals

  • ANMAT Local MOH
  • ANVISA Brazil
  • INVIMA Colombia
  • COFEPRIS Mexico
  • SFDA Saudi Arabia
  • MCC South Africa
  • GCC UAE – KSA
  • DRAP Pakistan
  • Ukrainian GMP
  • Sudan GMP
  • Syrian Arab Republic GMP
  • CHMP Kenya

Markets

Brazil, Mexico, Argentina, Vietnam, Indonesia, Caribbean countries, Other Latin American, Middle East and African countries

Annual Capacity

Injectables:

Liquid – 3 Mn Vials

Lyophilized – 1.3 Mn Vials

Vysoke Myto, Czech Republic

This manufacturing facility, formerly known as Medicamenta, was set-up in 1952 and was acquired by Glenmark in 2007. Presently the facility manufactures solid-orals.

OHSAS certification

Regulatory Approvals

  • Manufacturing licence for medicinal products (Issued by SUKL)
  • Distribution licence for medicinal products (Issued by SUKL)
  • Certificate of GMP Compliance of Manufacturer (Issued by SUKL)

Markets

Czech Republic, Slovakia, Poland

Annual Capacity

Oral solid dosages: 200 Mn tablets

Aurangabad, India

Glenmark’s Aurangabad facility initiated operations in April 2012. Aurangabad site is focused in the manufacturing of Formulations (OSD, Inhaler & Foam). This plant is spread over 30 acres and it serves to both domestic and international markets.

ISO 14001: 2015 approved, ISO 45001: 2018 approved

Regulatory Approvals

  • US-FDA
  • SUKL
  • WHO – GMP
  • ANMAT
  • ANVISA

Markets

ROW, Domestic, US, Brazil, EU

Annual Capacity

Tablet : 16 Mn

MDI : 3.5 Mn

DPI Device : 2 Mn

Topical Foam : 0.6 Mn

Quality at Glenmark

Setting new benchmarks through delivery of high quality products across all geographies
Know More